Disrupting Synthetic Biology: Kevin Munnelly, Gen9Submitted by Theral Timpson on Thu, 10/18/2012 - 08:42
Podcast brought to you by: Chempetitive Group - Who for more than a decade has helped science-based companies build and execute innovative marketing campaigns. "We love science. We love marketing. We love the idea of combining the two to make great things happen for your marketing communications."
Kevin Munnelly, CEO, Gen9 Bio and contact Info
Chapters: (Advance the marker)
0:39 A disruptive change to synthetic biology
6:56 Why hasn't gene synthesis progressed along with sequencing?
10:14 Looking at the market: applications for synthetic biology
15:29 Educating the market the biggest challenge
19:01 PR efforts going into biosecurity
25:07 Personal path to Gen9
As part of our series on synthetic biology, we talk with Kevin Munnelly, CEO of Gen9, a new gene synthesis company founded by George Church of Harvard, Joseph Jacobson of MIT, and Drew Endy of Stanford. According to Munnelly, Gen9 is not just another gene synthesis company, but one which will dramatically disrupt the space. The theory is that just as the declining cost of sequencing has enabled new applications for genomics, so too will a drastically reduced price for synthetic genes. Kevin believes we are just at the beginning of a synthetic biology revolution and it's new technology such as his that will enable it. What are these new applications and why hasn't gene synthesis kept pace with sequencing we ask Kevin in today's show.